VRTX
Vertex Pharmaceuticals Incorporated NASDAQ Listed Jul 24, 1991$508.34
-1.55%
vs $516.34
Mkt Cap $129.0B
52w Low $374.17
72.1% of range
52w High $560.25
50d MA $510.60
200d MA $470.15
P/E (TTM)
29.3x
EV/EBITDA
23.2x
P/B
7.0x
Debt/Equity
0.2x
ROE
21.2%
P/FCF
41.1x
RSI (14)
29.70
ATR (14)
$10.07
Beta
0.37
50d MA
$510.60
200d MA
$470.15
Avg Volume
1.1M
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
50 Northern Avenue · Boston, MA 02210 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | AMC | 4.74 | 4.73 | -0.2% | 470.72 | +0.1% | +1.7% | +1.3% | -0.2% | +2.5% | +5.6% | — |
| May 4, 2026 | AMC | 4.24 | 4.47 | +5.4% | 429.85 | +0.5% | -1.3% | +0.8% | -0.6% | +1.1% | +1.2% | — |
| Feb 12, 2026 | AMC | 5.11 | 5.03 | -1.6% | 465.02 | +1.4% | +5.7% | -2.9% | -1.5% | -0.2% | +1.6% | — |
| Nov 3, 2025 | AMC | 4.57 | 4.80 | +5.0% | 426.00 | -1.7% | -1.0% | -1.1% | -0.2% | -1.6% | +2.9% | — |
| Aug 4, 2025 | AMC | 4.29 | 4.52 | +5.4% | 472.27 | -13.6% | -20.6% | +2.8% | -2.6% | -2.4% | +2.2% | — |
| May 5, 2025 | AMC | 4.25 | 4.06 | -4.5% | 500.19 | -6.9% | -10.0% | -3.4% | -1.2% | -1.1% | +3.4% | — |
| Feb 10, 2025 | AMC | 4.02 | 3.98 | -1.0% | 469.97 | -2.2% | -3.1% | -0.4% | +2.1% | -0.8% | +0.7% | — |
| Nov 4, 2024 | AMC | 4.14 | 4.38 | +5.8% | 472.80 | +2.2% | +5.7% | -1.2% | +1.8% | +2.8% | -2.9% | — |
| Aug 1, 2024 | AMC | -11.63 | -12.83 | -10.3% | 505.78 | -2.8% | -2.2% | -3.5% | -0.5% | -1.8% | +0.0% | — |
| May 6, 2024 | AMC | 4.06 | 4.76 | +17.2% | 402.50 | +1.0% | +1.9% | +2.1% | +0.0% | +0.9% | +1.7% | — |
| Feb 5, 2024 | AMC | 4.10 | 4.20 | +2.4% | 428.89 | -0.0% | -3.0% | +0.7% | +0.9% | -0.0% | -1.0% | — |
| Nov 6, 2023 | AMC | 3.97 | 4.08 | +2.8% | 385.76 | -2.2% | -1.9% | -0.3% | -2.2% | +1.4% | +1.4% | — |
| Aug 1, 2023 | AMC | 3.88 | 3.89 | +0.3% | 347.74 | +0.6% | +3.1% | -3.0% | -2.1% | +1.4% | -0.2% | — |
| May 1, 2023 | AMC | 3.00 | 3.05 | +1.7% | 345.00 | +0.0% | +0.3% | +0.1% | +0.1% | +0.4% | -1.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 2 | Morgan Stanley | Reiterates | Overweight | $665 | $547.65 | $552.42 | +0.9% | +1.7% | +0.2% | -2.1% | -3.2% | -1.5% |
| May 27 | Truist | Reiterates | Buy | $542 | $435.93 | $438.52 | +0.6% | +0.3% | +2.5% | -0.1% | -2.0% | -3.0% |
| Apr 30 | Canaccord Genuity | Maintains | Hold → Hold | — | $423.24 | $423.66 | +0.1% | +1.0% | -0.8% | +1.4% | -1.3% | +0.8% |
| Apr 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $446.78 | $446.08 | -0.2% | -2.4% | +0.9% | +1.0% | -0.6% | -1.4% |
| Mar 18 | Maxim Group | Upgrade | Hold → Buy | — | $462.49 | $462.80 | +0.1% | -2.4% | +1.4% | -0.9% | -0.6% | -0.6% |
| Mar 11 | Truist | Maintains | Buy → Buy | — | $499.17 | $497.88 | -0.3% | -1.4% | -2.9% | -1.8% | -0.7% | -0.8% |
| Mar 10 | Citigroup | Maintains | Buy → Buy | — | $460.87 | $482.25 | +4.6% | +8.3% | -1.4% | -2.9% | -1.8% | -0.7% |
| Mar 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $460.87 | $482.25 | +4.6% | +8.3% | -1.4% | -2.9% | -1.8% | -0.7% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $460.87 | $482.25 | +4.6% | +8.3% | -1.4% | -2.9% | -1.8% | -0.7% |
| Mar 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $460.87 | $482.25 | +4.6% | +8.3% | -1.4% | -2.9% | -1.8% | -0.7% |
| Mar 10 | BofA Securities | Maintains | Buy → Buy | — | $460.87 | $482.25 | +4.6% | +8.3% | -1.4% | -2.9% | -1.8% | -0.7% |
| Feb 17 | Barclays | Maintains | Overweight → Overweight | — | $491.47 | $489.46 | -0.4% | -2.9% | -1.5% | -0.2% | +1.6% | +0.9% |
| Feb 17 | Canaccord Genuity | Maintains | Hold → Hold | — | $491.47 | $489.46 | -0.4% | -2.9% | -1.5% | -0.2% | +1.6% | +0.9% |
| Feb 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $491.47 | $489.46 | -0.4% | -2.9% | -1.5% | -0.2% | +1.6% | +0.9% |
| Feb 17 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $491.47 | $489.46 | -0.4% | -2.9% | -1.5% | -0.2% | +1.6% | +0.9% |
| Feb 13 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $465.02 | $471.65 | +1.4% | +5.7% | -2.9% | -1.5% | -0.2% | +1.6% |
| Feb 13 | Stifel | Maintains | Hold → Hold | — | $465.02 | $471.65 | +1.4% | +5.7% | -2.9% | -1.5% | -0.2% | +1.6% |
| Feb 13 | RBC Capital | Maintains | Outperform → Outperform | — | $465.02 | $471.65 | +1.4% | +5.7% | -2.9% | -1.5% | -0.2% | +1.6% |
| Feb 13 | Oppenheimer | Upgrade | Perform → Outperform | — | $465.02 | $471.65 | +1.4% | +5.7% | -2.9% | -1.5% | -0.2% | +1.6% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $465.02 | $471.65 | +1.4% | +5.7% | -2.9% | -1.5% | -0.2% | +1.6% |
| Jan 28 | Barclays | Upgrade | Equal Weight → Overweight | — | $474.17 | $474.09 | -0.0% | +0.8% | -0.5% | -1.2% | +0.4% | -1.4% |
| Jan 26 | UBS | Maintains | Buy → Buy | — | $468.41 | $470.79 | +0.5% | +1.8% | -0.6% | +0.8% | -0.5% | -1.2% |
| Jan 23 | Evercore ISI | Maintains | Outperform → Outperform | — | $467.35 | $465.23 | -0.5% | +0.2% | +1.8% | -0.6% | +0.8% | -0.5% |
| Jan 22 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $461.14 | $463.74 | +0.6% | +1.3% | +0.2% | +1.8% | -0.6% | +0.8% |
| Jan 12 | Bernstein | Upgrade | Market Perform → Outperform | — | $463.86 | $461.07 | -0.6% | -0.7% | -1.3% | -1.1% | -2.4% | +0.6% |
| Jan 6 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $448.80 | $454.85 | +1.3% | +4.4% | +3.4% | -3.0% | -1.2% | -0.7% |
| Dec 29 | Leerink Partners | Maintains | Outperform → Outperform | — | $462.90 | $463.00 | +0.0% | -0.7% | -1.3% | -0.1% | -0.3% | -0.7% |
| Dec 10 | Wells Fargo | Maintains | Overweight → Overweight | — | $437.01 | $438.81 | +0.4% | +1.7% | +0.3% | +1.4% | +0.8% | -0.2% |
| Dec 5 | Morgan Stanley | Maintains | Overweight → Overweight | — | $457.36 | $457.78 | +0.1% | -0.4% | -3.0% | -1.1% | +1.7% | +0.3% |
| Dec 3 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $433.15 | $440.31 | +1.7% | +6.9% | -1.2% | -0.4% | -3.0% | -1.1% |
| Nov 7 | UBS | Maintains | Buy → Buy | — | $416.25 | $415.61 | -0.2% | -1.6% | +2.9% | +1.9% | +1.2% | +0.1% |
| Nov 4 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $426.00 | $418.55 | -1.7% | -1.0% | -1.1% | -0.2% | -1.6% | +2.9% |
| Nov 4 | Barclays | Maintains | Equal Weight → Equal Weight | — | $426.00 | $418.55 | -1.7% | -1.0% | -1.1% | -0.2% | -1.6% | +2.9% |
| Nov 4 | Stifel | Maintains | Hold → Hold | — | $426.00 | $418.55 | -1.7% | -1.0% | -1.1% | -0.2% | -1.6% | +2.9% |
| Oct 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $414.86 | $413.33 | -0.4% | -1.7% | -0.1% | +1.2% | -1.0% | +0.2% |
| Oct 8 | JP Morgan | Maintains | Overweight → Overweight | — | $410.28 | $410.93 | +0.2% | +2.6% | -1.5% | -1.7% | -0.1% | +1.2% |
| Oct 2 | Citigroup | Maintains | Buy → Buy | — | $404.21 | $404.21 | +0.0% | +1.1% | -1.4% | -0.1% | +1.8% | +2.6% |
| Sep 25 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $376.62 | $383.20 | +1.7% | +1.4% | +1.0% | +2.5% | -0.9% | +3.2% |
| Sep 11 | Evercore ISI | Maintains | Outperform → Outperform | — | $388.55 | $388.55 | +0.0% | +2.3% | -0.7% | -0.3% | -0.5% | -1.1% |
| Aug 7 | Citigroup | Maintains | Buy → Buy | — | $385.65 | $385.00 | -0.2% | -2.6% | -2.4% | +2.2% | +3.6% | +2.1% |
| Aug 6 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $374.98 | $375.76 | +0.2% | +2.8% | -2.6% | -2.4% | +2.2% | +3.6% |
| Aug 6 | Canaccord Genuity | Maintains | Hold → Hold | — | $374.98 | $375.76 | +0.2% | +2.8% | -2.6% | -2.4% | +2.2% | +3.6% |
| Aug 6 | Guggenheim | Maintains | Buy → Buy | — | $374.98 | $375.76 | +0.2% | +2.8% | -2.6% | -2.4% | +2.2% | +3.6% |
| Aug 5 | UBS | Maintains | Buy → Buy | — | $472.27 | $408.22 | -13.6% | -20.6% | +2.8% | -2.6% | -2.4% | +2.2% |
| Aug 5 | Truist | Maintains | Buy → Buy | — | $472.27 | $408.22 | -13.6% | -20.6% | +2.8% | -2.6% | -2.4% | +2.2% |
| Aug 5 | BMO Capital | Maintains | Outperform → Outperform | — | $472.27 | $408.22 | -13.6% | -20.6% | +2.8% | -2.6% | -2.4% | +2.2% |
| Aug 5 | Stifel | Maintains | Hold → Hold | — | $472.27 | $408.22 | -13.6% | -20.6% | +2.8% | -2.6% | -2.4% | +2.2% |
| Aug 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $472.27 | $408.22 | -13.6% | -20.6% | +2.8% | -2.6% | -2.4% | +2.2% |
| Aug 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $472.27 | $408.22 | -13.6% | -20.6% | +2.8% | -2.6% | -2.4% | +2.2% |
| Aug 5 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $472.27 | $408.22 | -13.6% | -20.6% | +2.8% | -2.6% | -2.4% | +2.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | McKechnie DuncanOff | EVP, Chief Commercial Officer | Sell | 1,541 | $519.00 | $800K | 11,001 | -4.56% | -0.82% |
| Jul 2, 2026 | Tatsis OuraniaOff | EVP, Chief Reg. & Quality Off. | Sell | 1,500 | $524.99 | $787K | 45,321 | -4.56% | -0.82% |
| Jul 1, 2026 | Liu JoyOff | EVP and Chief Legal Officer | Sell | 828 | $502.71 | $416K | 19,131 | -1.39% | -1.06% |
| Jun 26, 2026 | Bozic CarmenOff | EVP and CMO | Sell | 596 | $482.50 | $288K | 15,337 | +0.26% | -4.56% |
| Jun 18, 2026 | Bozic CarmenOff | EVP and CMO | Sell | 1,020 | $462.17 | $471K | 15,933 | +1.45% | -0.58% |
| Jun 15, 2026 | Bozic CarmenOff | EVP and CMO | Sell | 4,062 | $450.00 | $1.8M | 16,953 | -1.60% | +1.05% |
| Jun 5, 2026 | Bozic CarmenOff | EVP and CMO | Sell | 1,745 | $450.00 | $785K | 21,015 | -2.26% | +0.60% |
| Jun 1, 2026 | Liu JoyOff | EVP and Chief Legal Officer | Sell | 828 | $439.91 | $364K | 19,959 | +3.13% | -2.26% |
| May 29, 2026 | Bozic CarmenOff | EVP and CMO | Sell | 1,974 | $450.00 | $888K | 22,760 | +0.76% | +0.63% |
| May 15, 2026 | Bunnage Mark E.Off | EVP, Chief Scientific Officer | Sell | 33 | $453.45 | $15K | 7,284 | -0.89% | +0.30% |
| May 15, 2026 | Bozic CarmenOff | EVP and CMO | Sell | 1,354 | $453.45 | $614K | 24,734 | -0.89% | +0.30% |
| May 12, 2026 | Bozic CarmenOff | EVP and CMO | Sell | 6,988 | $450.00 | $3.1M | 26,088 | -2.99% | +0.72% |
| May 4, 2026 | Bhatia Sangeeta N.Dir | — | Sell | 318 | $423.73 | $135K | 4,924 | +0.78% | +3.01% |
| May 1, 2026 | Liu JoyOff | EVP and Chief Legal Officer | Sell | 1,104 | $425.02 | $469K | 20,729 | +0.78% | +3.01% |
8-K · 2.01
!!! Very High
Crinetics Pharmaceuticals, Inc. -- 8-K 2.01: Acquisition Completed
Sep 1
8-K · 2.02
!! High
AbCellera Biologics Inc. -- 8-K 2.02: Earnings Results
Aug 5
8-K · 2.02
!! High
Crinetics Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
Crinetics Pharmaceuticals reported second-quarter 2026 financial results, providing investors with updated operational performance and financial metrics for the period ending June 30, 2026.
Aug 3
8-K · 8.01
!! High
AbCellera Biologics Inc. -- 8-K 8.01: Material Event / Announcement
Jul 29
8-K · 7.01
! Medium
Vertex Pharmaceuticals Incorporated -- 8-K 7.01: Regulation FD Disclosure
Jul 7
8-K · 5.02
!!! Very High
Vertex Pharmaceuticals Incorporated -- 8-K 5.02: Executive Change
May 13
8-K · 5.02
!!! Very High
Vertex Pharmaceuticals Inc -- 8-K 5.02: Executive Change
Vertex Pharmaceuticals appointed and simultaneously had Suketu Upadhyay resign as director, suggesting a potential leadership transition or restructuring that investors should monitor for strategic implications.
Apr 29
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
VRTX's vague forward-looking statement caution suggests upcoming announcements may disappoint if projections don't materialize, warranting investor caution on stock volatility.
Mar 31
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Absci's rapid progression of AI-designed ABS-201 into human trials with positive safety signals validates its platform technology, potentially justifying higher valuations if clinical efficacy data continues to impress investors.
Mar 24
8-K
Vertex Pharmaceuticals Inc -- 8-K Filing
Vertex Pharmaceuticals expects accelerated FDA approval of povetacicept for IgAN in the first half of 2026, potentially adding a new revenue stream while the company advances its cystic fibrosis and gene therapy portfolios.
Feb 12
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | 24,109,373 | $12.0B | New | Jun 2026 |
| 2 | Capital World Investors | 25,368,124 | $11.3B | Reduced | Mar 2026 |
| 3 | Capital Research Global Investors | 21,125,964 | $9.4B | Added | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 16,580,713 | $8.2B | — | Jun 2026 |
| 5 | Jpmorgan Chase & Co | 7,033,156 | $3.1B | Added | Mar 2026 |
| 6 | Morgan Stanley | 6,240,620 | $2.8B | — | Dec 2025 |
| 7 | Vanguard Portfolio Management Llc | 4,878,987 | $2.4B | Reduced | Jun 2026 |
| 8 | Jennison Associates Llc | 2,998,530 | $1.5B | Reduced | Jun 2026 |
| 9 | Norges Bank | 2,971,681 | $1.5B | New | Jun 2026 |
| 10 | Bank Of America Corp /de/ | 2,878,183 | $1.3B | Added | Mar 2026 |
| 11 | Clearbridge Investments, Llc | 2,700,975 | $1.2B | Reduced | Mar 2026 |
| 12 | Northern Trust Corp | 2,564,264 | $1.1B | Reduced | Mar 2026 |
| 13 | Invesco Ltd. | 2,561,057 | $1.1B | Added | Mar 2026 |
| 14 | Janus Henderson Group Plc | 2,131,527 | $952M | New | Mar 2026 |
| 15 | Fmr Llc | 2,020,265 | $902M | Reduced | Mar 2026 |
| 16 | Victory Capital Management Inc | 1,888,521 | $843M | Reduced | Mar 2026 |
| 17 | Bank Of New York Mellon Corp | 1,586,427 | $708M | Added | Mar 2026 |
| 18 | Nuveen, Llc | 1,081,685 | $537M | — | Jun 2026 |
| 19 | Citadel Advisors Llc | 1,020,860 | $507M | Added | Jun 2026 |
| 20 | Royal Bank Of Canada | 1,111,871 | $496M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity 500 Index Fund | 3,228,892 | $1.6B | Feb 2026 |
| 2 | iShares Core S&P 500 ETF | 3,266,609 | $1.5B | Mar 2026 |
| 3 | Capital World Growth & Income Fund | 2,273,163 | $1.1B | Feb 2026 |
| 4 | Washington Mutual Investors Fund | 2,392,362 | $1.1B | Jan 2026 |
| 5 | VANGUARD HEALTH CARE FUND | 1,589,663 | $747M | Jan 2026 |
| 6 | New Economy Fund | 1,320,751 | $656M | Feb 2026 |
| 7 | JPMorgan Equity Premium Income ETF | 1,319,151 | $655M | Jun 2026 |
| 8 | iShares Biotechnology ETF | 1,354,033 | $605M | Mar 2026 |
| 9 | Invesco NASDAQ 100 ETF | 1,079,409 | $483M | May 2026 |
| 10 | Capital Group Dividend Value ETF | 882,131 | $438M | Feb 2026 |
| 11 | Capital Group Growth ETF | 766,745 | $381M | Feb 2026 |
| 12 | American Funds Global Balanced Fund | 773,820 | $364M | Jan 2026 |
| 13 | AB LARGE CAP GROWTH FUND INC | 715,223 | $336M | Jan 2026 |
| 14 | Harbor Capital Appreciation Fund | 697,220 | $328M | Jan 2026 |
| 15 | iShares MSCI USA Min Vol Factor ETF | 656,687 | $309M | Jan 2026 |
| 16 | iShares Russell 1000 Value ETF | 567,848 | $282M | Jun 2026 |
| 17 | Schwab S&P 500 Index Fund | 570,035 | $268M | Jan 2026 |
| 18 | JPMorgan U.S. Equity Fund | 502,245 | $249M | Jun 2026 |
| 19 | Schwab U.S. Large-Cap Growth ETF | 541,983 | $243M | May 2026 |
| 20 | JPMorgan Nasdaq Equity Premium Income ETF | 483,197 | $240M | Jun 2026 |
Valuation
Market Cap
$129.02B
Enterprise Value
$126.39B
P/E (TTM)
29.29x
Forward P/E
26.52x
PEG Ratio
-0.03x
P/B
6.96x
P/S
10.22x
P/FCF
41.06x
EV/EBITDA
23.21x
Shares Out
258.0M
Financials (TTM)
Revenue
$12.62B
Net Income
$4.41B
EBITDA
$5.44B
Free Cash Flow
$3.19B
Op Cash Flow
$3.63B
EPS Basic
$15.46
EPS Diluted
$17.18
EPS Forward
$19.16
Gross Margin
86.0%
Op Margin
38.6%
Net Margin
34.9%
Balance Sheet
Total Assets
$26.14B
Total Liab.
$7.48B
Total Equity
$18.67B
Cash
$6.61B
LT Debt
$1.85B
Book Value/Sh
$73.00
Debt/Equity
0.21x
Current Ratio
2.90
Quick Ratio
2.46
Returns & Growth
ROE
21.2%
ROA
15.4%
ROIC
18.1%
Rev Growth YoY
+9.6%
EPS Growth YoY
+843.3%
Price Returns
2W
-8.9%
1M
-7.9%
3M
+8.9%
6M
+11.0%
12M
+32.7%
Technicals
52W High
$560.25
52W Low
$374.17
50d MA
$510.60
200d MA
$470.15
RSI (14)
29.70
ATR (14)
$10.07
Beta
0.37
Avg Volume
1.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$552.27
High
$612.00
Low
$437.00
Median
$558.00
Data updated apr 27, 2026 8:11am
· Source: financialmodelingprep.com